Table 5 Characteristics of patients with a high Charlson Comorbidity Index (≥5 points) as well as pharmacokinetics and pharmacodynamics of vancomycin
Characteristic | All patients (N = 22) | 30-day all-cause mortality group (N = 10) | Survival group (N = 12) | P-value† |
|---|---|---|---|---|
Body weight (kg)a | 52.7 (45.7–63.0) | 60.4 (46.8–71.0) | 48.7 (42.6–54.3) | 0.044 i) |
WBC (× 103/μL)a | 9.1 (4.0–13.2) | 13.2 (7.4–17.4) | 5.8 (3.5–11.4) | 0.048 i) |
PLT (× 103/μL)a | 154 (97.5–206.5) | 102 (76–152) | 181 (125–292) | 0.021 i) |
CCIa | 6 (6–7) | 6 (6–8) | 6 (6–7) | 0.77 i) |
SOFA score (a) | 2 (1–5) | 2 (1–6) | 1 (1–5) | 0.40 i) |
SOFA score (b) | 3 (1–6) | 6 (4–7) | 2 (0–2) | 0.014 i) |
Acute kidney injury patients¶ | 8 (36.4%) | 4 (40.0%) | 4 (33.3%) | 1.00 ii) |
ARC risk scorea | 1 (0–1) | 1 (0–1) | 1 (0–1) | 0.57 i) |
Pharmacokinetics and pharmacodynamics of vancomycin | ||||
Vancomycin trough concentration (μg/mL)a | 14.8 (9.9–25.3) | 23.2 (14.4–28.3) | 10.5 (8.9–15.7) | 0.0069 i) |
Vancomycin AUC24 (μg/mL·h)a | 721 (498–943) | 745 (488–885) | 658 (499–1065) | 1.00 i) |
Vancomycin AUC24/MIC ratioa | 826 (561–1142) | 859 (663–1194) | 730 (515–1242) | 0.74 i) |
Number of cases with failure to achieve a vancomycin AUC24/MIC ratio ≤ 389 | 10 (45.5%) | 5 (50.0%) | 5 (41.7%) | 1.00 ii) |